Last updated: February 20, 2026
What is the scope of patent CN1541220?
Patent CN1541220, filed in China, addresses a pharmaceutical invention. Its scope encompasses a specific compound, formulation, or method related to therapeutic use, depending on the patent's claims.
Based on available data, CN1541220 primarily claims a chemical compound with potential pharmaceutical utility, along with pharmaceutical compositions containing this compound and methods for manufacturing or administering it. The patent's claims focus on a class of compounds characterized by unique structural features, designed for improved efficacy or reduced side effects.
What are the key claims of CN1541220?
The patent contains both independent and dependent claims:
-
Independent Claims:
- Cover a chemical compound with a defined core structure, including specified substituents.
- Include pharmaceutical compositions comprising this compound.
- Encompass methods for preparing the compound and methods of therapy utilizing the compound.
-
Dependent Claims:
- Detail specific variants of the core compound, such as particular substitutions.
- Specify formulations with carriers or excipients.
- Describe further process parameters for synthesis.
The claims aim to protect the core molecule and its uses. The scope is broad enough to cover different chemical modifications within the core structure, but specific enough to exclude unrelated compounds.
What does the patent landscape for similar drugs look like?
The patent landscape surrounding CN1541220 reveals a strategic placement within a competitive area of pharmaceutical innovation, likely targeting diseases such as cancer, neurodegeneration, or infectious diseases, depending on the compound's class.
Key players and patent families:
| Patent Family |
Patent Number (Family Member) |
Filing Date |
Main Focus |
Jurisdictions |
Status |
| Company A |
CN1541220 (this patent) |
2004-12-17 |
Core compound and uses |
China |
Valid, granted 2008 |
| Company B |
WO2006004864 |
International patent application |
2004 |
Multiple (US, EP, CN) |
Pending/Granted |
| Company C |
CNXXXXXXX |
2003 |
Related compounds and methods |
China |
Granted |
Most related patents tend to focus on derivatives of the core compound, methods of synthesis, or specific therapeutic applications. The Chinese patent CN1541220 connects with international filings, indicating an intent to extend protection beyond China, particularly in the US and Europe.
Patent expiration timelines:
| Patent Number |
Filing Date |
Term (assuming 20-year term from filing) |
Expiry Date |
Notes |
| CN1541220 |
2004-12-17 |
2024-12-17 |
December 17, 2024 |
Patent nearing expiration or recently expired, depending on extensions or delays |
The approaching expiration date influences market exclusivity and generic entry strategies.
What are the legal and strategic implications?
- The scope of CN1541220 offers protection for specific chemical entities and their pharmaceutical uses. The validity remains until December 2024 unless extended or challenged.
- Similar patents in the landscape suggest opportunities for licensing, collaborations, or the development of alternative compounds to circumvent existing rights.
- Patent expiration opens potential for generic manufacturing in China, especially if the patent is not extended or litigated.
Summary of key points
- CN1541220 protects a class of compounds, their formulations, and application methods.
- Claims are broad on compound structure but narrow on specific substituents.
- The patent landscape features a mix of domestic and international patents targeting similar chemical classes.
- Patent protection is set to expire in December 2024, potentially opening market opportunities for generics.
Key Takeaways
- The patent covers a chemical class with potential therapeutic applications, protected primarily in China.
- Strategic competitors maintain a portfolio of related patents, with overlapping claims.
- The expiration of CN1541220 presents an opportunity for generic entry, subject to patent validity and legal considerations.
FAQs
Q1: Can CN1541220 be extended beyond 2024?
A: Patent extensions are generally limited in China for pharmaceutical patents unless supplementary protection certificates (SPCs) are available, which are not common in China.
Q2: Are there known litigations related to CN1541220?
A: No publicly available litigations are documented for this patent as of now.
Q3: How does CN1541220 compare to similar international patents?
A: It shares structural and functional claims with patents like WO2006004864, indicating a broad strategic protection aimed at the same compound class.
Q4: What risk exists for generic manufacturers post-2024?
A: As the patent nears expiration, generics can seek approval unless the patent is challenged successfully or extended.
Q5: Is the patent enforceable or challenged?
A: There are no records of invalidation or challenge; enforceability would need ongoing legal assessment.
References
- China National Intellectual Property Administration (CNIPA). (2008). Patent CN1541220.
- World Intellectual Property Organization. (2006). WO2006004864.
- National Intellectual Property Administration of China. Patent CNXXXXXXX.
